Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder

Objective: To further define the efficacy and safety profiles of lisdexamfetamine dimesylate (LDX) in Japanese pediatric patients with attention-deficit/hyperactivity disorder (ADHD). Methods: This was a multicenter, randomized, double-blind, placebo-controlled study of LDX 30, 50, or 70 mg/day for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Child Adolesc Psychopharmacol
Main Authors: Ichikawa, Hironobu, Miyajima, Tasuku, Yamashita, Yushiro, Fujiwara, Masakazu, Fukushi, Akimasa, Saito, Kazuhiko
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7041327/
https://ncbi.nlm.nih.gov/pubmed/31718254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2019.0076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados